HMAs were reported to demethylate and upregulate endogenous viral double‐stranded RNA (dsRNA), which was detected by dsRNA sensors, triggering interferon (IFN) anticancer immune responses.[1, 2, 3] DAC has been reported to have striking efficacy in the treatment of some AML and MDS subtypes, such as the highly refractory TP53‐mutant AML/MDS.[4] Despite the widely recognized efficacy of the HMA, most HMA‐treated AML/MDS patients relapsed.[4, 5, 6]. The gene discussed is TP53; the disease is acute myeloid leukemia.